SIGNal peptides Indicative For Immediate Cardiac and Anti-pneumonic Treatment in acute Heart Failure
Not Applicable
Recruiting
- Conditions
- Acute Heart FailurepneumoniaCardiovascular - Coronary heart diseaseInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12614000948695
- Lead Sponsor
- Christchurch Heart Institute. University of Otago
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
Eligible patients who report shortness of breath not due to trauma as their primary complaint upon presentation to the ED.
Exclusion Criteria
Patients under 18 years of age or unable to provide consent are excluded.
Patients with an acute ST-elevation myocardial infarction and patients on haemodialysis for renal failure are also excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum assay results will be used to assess the performance of signal peptides in early detection of pneumonia complicating Acute Decompensated Heart Failure (ADHF)[ 30, 90 and 365 days ]
- Secondary Outcome Measures
Name Time Method Serum assay results will be used to identify a superior marker with the potential to be tested in a study of marker guidance of early antibiotic treatment in complicated ADHF.[ outcome assessed at 30, 90 and 365 days by serum assay];The prognostic utility of markers for all-cause mortality[ 30, 90 and 365 days by data linkage to patient medical records]; readmission with HF, pneumonia or other infection[ 30, 90 and 365 days by data linkage to patient medical records to adjudicate readmission discharge diagnoses];all cardiovascular and infectious events and all readmissions[ 30, 90 and 365 days by data linkage to patient medical records to adjudicate readmission discharge diagnoses]